

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

JVM-13

RRID:CVCL_1318

Type: Cell Line

Proper Citation

ATCC Cat# CRL-3003, RRID:CVCL_1318

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1318

Proper Citation: ATCC Cat# CRL-3003, RRID:CVCL_1318

Description: Cell line JVM-13 is a Transformed cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Mantle cell lymphoma

Defining Citation: [PMID:3262465](#), [PMID:20454443](#), [PMID:24362935](#), [PMID:25315077](#), [PMID:25960936](#), [PMID:28196595](#), [PMID:29666304](#), [PMID:31160637](#)

Comments: Part of: MD Anderson Cell Lines Project., Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank)., Part of: LL-100 blood cancer cell line panel.

Category: Transformed cell line

Organism: Homo sapiens (Human)

Name: JVM-13

Synonyms: JVM 13, JVM13

Cross References: CLO:CLO_0007046, CLDB:cl2964, CLDB:cl5073, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ATCC:CRL-3003, BioSample:SAMN01821571, BioSample:SAMN01821641, BioSample:SAMN03471707, DSMZ:ACC-19, DSMZCellDive:ACC-19, ECACC:96090516, GEO:GSM1266785, GEO:GSM1266786, Wikidata:Q54899190

ID: CVCL_1318

Vendor: ATCC

Catalog Number: CRL-3003

Record Creation Time: 20220427T220653+0000

Record Last Update: 20260905T180919+0000

Ratings and Alerts

No rating or validation information has been found for JVM-13.

No alerts have been found for JVM-13.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wu JL, et al. (2022) Phosphoproteomics Reveals the Role of Constitutive KAP1 Phosphorylation by B-cell Receptor Signaling in Chronic Lymphocytic Leukemia. Molecular cancer research : MCR, 20(8), 1222.

Demajo S, et al. (2021) A Cyclin D1-Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(1), 213.

Portelinha A, et al. (2021) ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. Cell reports. Medicine, 2(7), 100350.